Search clinical trials for: AZD8329

Total 60 results

AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
AstraZeneca

Completed

A Study Conducted Over 3 Periods to Look at the Drug in the Body

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca

Completed

AZD8529 Single Ascending Dose Study (SAD)

Healthy Volunteer

United States
AstraZeneca

Completed

AZD8529 Multiple Ascending Dose Study in Healthy Subjects

Healthy Volunteer
AstraZeneca

Completed

AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects (JSAD)

Healthy

United Kingdom
National Institute on Drug Abuse (NIDA)

Completed

The Study of AZD8529 for Smoking Cessation in Female Smokers

Tobacco Use Disorder

United States
AstraZeneca

Completed

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

Healthy | Memory Impairment

United States
AstraZeneca

Completed

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Healthy Volunteers | Alzheimer's Disease | Tolerability | Safety | Blood Concentration

United Kingdom
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329 (AZ8329)

Healthy | Overweight | Male

United Kingdom
AstraZeneca

Completed

A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses

Healthy Men

Sweden
AstraZeneca

Recruiting

Study of AZD9829 in CD123+ Hematological Malignancies

Hematological Malignancies

United States, Spain, Korea, Republic of, Italy, Japan, Taiwan, Australia, Germany, China
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Hypercholesterolemia

United States
AstraZeneca

Completed

To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328

Healthy

Sweden
AstraZeneca

Completed

A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

Healthy

Sweden
AstraZeneca

Completed

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (AZD3293hADME)

Healthy Volunteers | Mass Balance Study

United States
AstraZeneca

Suspended

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

Metabolism | Absorption | Distribution | Excretion

United Kingdom
AstraZeneca

Completed

AZD7325 Multiple Ascending Dose Study (MAD)

Healthy Volunteer

United States
AstraZeneca
Parexel

Terminated

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

End Stage Renal Disease

Poland
AstraZeneca

Completed

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

Anxiety Disorders

United States
AstraZeneca

Terminated

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

Schizophrenia

United States
AstraZeneca

Completed

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects (JSAD)

Healthy Volunteer

United States
Children's Hospital Medical Center, Cincinnati

Completed

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

Fragile X Syndrome

United States
AstraZeneca

Terminated

AZD7325 Japan Multiple Ascending Dose (MAD) Study (JMAD)

Healthy
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Alzheimer's Disease

United States, Spain, Australia, Belgium, Korea, Republic of, United Kingdom, Germany, Poland, Canada, Japan, Romania, France, Puerto Rico, Hungary
AstraZeneca

Completed

AZD8330 First Time in Man in Patients With Advanced Malignancies

Cancer

United States, Norway
AstraZeneca

Completed

Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (BA)

Healthy Volunteers | Pharmacologic Action

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy
University College, London

Completed

Effects of GABA Modulator AZD7325 on Cortical Excitability

Healthy

United Kingdom
AstraZeneca
Parexel

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

Dyslipidemia

United States
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (DAYBREAK-ALZ)

Alzheimer's Disease

United States, Spain, Korea, Republic of, Italy, Portugal, China, Taiwan, Czechia, Japan, Poland, France, Netherlands, United Kingdom, Germany, Russian Federation, Canada, Mexico, Denmark
AstraZeneca
Eli Lilly and Company

Terminated

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH)

Alzheimer´s Disease

United States, Spain, Belgium, Australia, Hungary, Korea, Republic of, Canada, Germany, Japan, Romania, France, Poland, United Kingdom, Puerto Rico, Italy
University of California, Los Angeles

Completed

Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial (FAST-AS)

Autism Spectrum Disorder

United States
King's College London
AstraZeneca; Helse Stavanger HF; Michael J. Fox Foundation for Parkinson's Research and other collaborators

Withdrawn

Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug (PD-MIND)

Parkinson Disease | Mild Cognitive Impairment
AstraZeneca

Completed

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia (SOLANO)

Hyperlipidaemia

Denmark, Netherlands, Spain, Czechia, United States, Slovakia, Hungary, Poland
AstraZeneca

Completed

Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)

Anxious Major Depressive Disorder

United States
AstraZeneca

Recruiting

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Healthy Participants

United States
AstraZeneca

Completed

Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
AstraZeneca

Completed

A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers

Japan
AstraZeneca

Completed

A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

Healthy Elderly Volunteers | Mild-to-moderate Alzheimer's Disease Patients

United States
AstraZeneca

Completed

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

Healthy Elderly Volunteers | Healthy Young Volunteers

United States
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects

Alzheimer's Disease

Sweden
AstraZeneca
Eli Lilly and Company

Completed

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Healthy

United States
University College, London

Completed

Effects of GABA Modulator AZD7325 on Cutaneous Sensation

Healthy

United Kingdom
Sichuan University

Recruiting

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Multiple Myeloma

China
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia. (HAYATE)

Dyslipidemia

Japan
Luca Ronfani
University of Trieste

Completed

Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models

Urea Cycle Disorders, Inborn | Other Metabolic Diseases

Italy
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

Korea, Republic of, United Kingdom, Australia, United States, Spain
AstraZeneca

Suspended

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

Pharmacokinetics

United States
AstraZeneca
Eli Lilly and Company

Completed

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy

United States

3

Subscribe